中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2357-2363

Association between thyroxine level and nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.10.020

  • Department of Gastroenterology, PLA Rocket Forces Characteristic Medical Center, Beijing 100088, China

Research funding:

Project of Beijing Science and Technology Program (Z1511000040150070)

  • Received Date: 2021-03-24
  • Accepted Date: 2021-05-20
  • Published Date: 2021-10-20
    Abstract
  •   Objective  To investigate the association between thyroxine level and nonalcoholic fatty liver disease (NAFLD).  Methods  A retrospective analysis was performed for 3289 subjects who underwent physical examination in PLA Rocket Force Characteristic Medical Center from July 2015 to April 2019, and according to medical history and thyroid function, they were divided into subclinical hypothyroidism group with 210 subjects and normal thyroid function group with 3079 subjects. According to the results of abdominal color Doppler ultrasound, the normal thyroid function group was divided into NAFLD group with 516 subjects and non-NAFLD group with 2563 subjects; according to body mass index (BMI), the normal thyroid function group was divided into non-obese group (BMI < 25 kg/m2) and obese group (BMI ≥25 kg/m2); according to the age, the normal thyroid function group was divided into elderly group (age ≥60 years) and young and middle-aged group (age < 60 years). The normal thyroid function group was typed based on age and body type. Related data were collected, including sex, age, BMI, blood pressure, waist circumference, fasting blood glucose, uric acid, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, free triiodothyronine, free thyroxine, triiodothyronine, thyroxine, and thyroid stimulating hormone (TSH). The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test used for comparison of categorical data between two groups. A multivariate logistic regression analysis was used to investigate risk factors, and the receiver operator characteristic (ROC) curve was used to analyze the cut-off values of related indices in predicting NAFLD.  Results  The subclinical hypothyroidism group had a higher prevalence rate of NAFLD than the normal thyroid function group (22.38% vs 16.76%, χ2=4.380, P=0.036), and in the subclinical hypothyroidism group, the NAFLD patients had a higher level of TSH than the non-NAFLD patients(Z=-1.994, P=0.046). In the subclinical hypothyroidism group, there were no significant differences in thyroid parameters between the NAFLD group and the non-NAFLD group (all P > 0.05); after stratification based on age and body type, in the obese-young and middle-aged subgroup, male sex, low free thyroxine, fasting blood glucose, and triglyceride were independent risk factors for NAFLD (odds ratio=4.729, 0.067, 1.814, and 1.717, P=0.003, 0.010, 0.011, and 0.014). The cut-off values of free thyroxine, fasting blood glucose, and triglyceride were 1.123 ng/dL, 5.15 mmol/L, and 1.02 mmol/L, respectively, in predicting NAFLD, and the area under the ROC curve was 0.832 for combined prediction.  Conclusion  There is a high prevalence rate of NAFLD in the population with subclinical hypothyroidism, and when thyroid function is within the normal range, low free thyroxine is associated with the onset of NAFLD in the young and middle-aged obese people.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    IQBAL U, PERUMPAIL BJ, AKHTAR D, et al. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease[J]. Medicines (Basel), 2019, 6(1): 41. DOI: 10.3390/medicines6010041.
    [2]
    SINHA RA, SINGH BK, YEN PM. Direct effects of thyroid hormones on hepatic lipid metabolism[J]. Nat Rev Endocrinol, 2018, 14(5): 259-269. DOI: 10.1038/nrendo.2018.10.
    [3]
    MANTOVANI A, NASCIMBENI F, LONARDO A, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Thyroid, 2018, 28(10): 1270-1284. DOI: 10.1089/thy.2018.0257.
    [4]
    XU R, HUANG F, ZHANG S, et al. Thyroid function, body mass index, and metabolic risk markers in euthyroid adults: A cohort study[J]. BMC Endocr Disord, 2019, 19(1): 58. DOI: 10.1186/s12902-019-0383-2.
    [5]
    RAHBAR AR, KALANTARHORMOZI M, IZADI F, et al. Relationship between Body Mass Index, Waist-to-Hip Ratio, and Serum Lipid Concentrations and Thyroid-Stimulating Hormone in the euthyroid adult population[J]. Iran J Med Sci, 2017, 42(3): 301-305.
    [6]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [7]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
    [8]
    WANG YH, GAO Y. Research progress in diagnosis and treatment of non-alcoholic fatty liver disease combinated with type 2 diabetes mellitus[J]. J Jilin Univ(Med Edit), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.

    王雨涵, 高影. 非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1324-1331. DOI: 10.13481/j.1671-587x.20200634.
    [9]
    DUNTAS LH, BRENTA G. A Renewed focus on the association between thyroid hormones and lipid metabolism[J]. Front Endocrinol (Lausanne), 2018, 9: 511. DOI: 10.3389/fendo.2018.00511.
    [10]
    SINHA RA, SINGH BK, YEN PM. Reciprocal crosstalk between autophagic and endocrine signaling in metabolic homeostasis[J]. Endocr Rev, 2017, 38(1): 69-102. DOI: 10.1210/er.2016-1103.
    [11]
    CHI HC, TSAI CY, TSAI MM, et al. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases[J]. J Biomed Sci, 2019, 26(1): 24. DOI: 10.1186/s12929-019-0517-x.
    [12]
    CHAKRAVARTHY MV, NEUSCHWANDER-TETRI BA. The metabolic basis of nonalcoholic steatohepatitis[J]. Endocrinol Diabetes Metab, 2020, 3(4): e00112. DOI: 10.1002/edm2.112.
    [13]
    FERRANDINO G, KASPARI RR, SPADARO O, et al. Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms[J]. Proc Natl Acad Sci U S A, 2017, 114(43): e9172-e9180. DOI: 10.1073/pnas.1707797114.
    [14]
    VERGANI L. Lipid lowering effects of iodothyronines: In vivo and in vitro studies on rat liver[J]. World J Hepatol, 2014, 6(4): 169-177. DOI: 10.4254/wjh.v6.i4.169.
    [15]
    LIU Y, WANG W, YU X, et al. Thyroid function and risk of non-alcoholic fatty liver disease in euthyroid subjects[J]. Ann Hepatol, 2018, 17(5): 779-788. DOI: 10.5604/01.3001.0012.3136.
    [16]
    BORGES-CANHA M, NEVES JS, MENDONÇA F, et al. Thyroid function and the risk of non-alcoholic fatty liver disease in morbid obesity[J]. Front Endocrinol (Lausanne), 2020, 11: 572128. DOI: 10.3389/fendo.2020.572128.
    [17]
    van den BERG EH, van TIENHOVEN-WIND LJ, AMINI M, et al. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: The Lifelines Cohort Study[J]. Metabolism, 2017, 67: 62-71. DOI: 10.1016/j.metabol.2016.11.002.
    [18]
    JARUVONGVANICH V, SANGUANKEO A, UPALA S. Nonalcoholic fatty liver disease is not associated with thyroid hormone levels and hypothyroidism: A systematic review and meta-analysis[J]. Eur Thyroid J, 2017, 6(4): 208-215. DOI: 10.1159/000454920.
    [19]
    DUNTAS LH. Thyroid function in aging: A discerning approach[J]. Rejuvenation Res, 2018, 21(1): 22-28. DOI: 10.1089/rej.2017.1991.
    [20]
    LIU G, LIANG L, BRAY GA, et al. Thyroid hormones and changes in body weight and metabolic parameters in response to weight loss diets: The POUNDS LOST trial[J]. Int J Obes (Lond), 2017, 41(6): 878-886. DOI: 10.1038/ijo.2017.28.
    [21]
    BRIL F, KADIYALA S, PORTILLO SANCHEZ P, et al. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes[J]. J Investig Med, 2016, 64(1): 63-68. DOI: 10.1136/jim-2015-000019.
    [22]
    ITTERMANN T, HARING R, WALLASCHOFSKI H, et al. Inverse association between serum free thyroxine levels and hepatic steatosis: Results from the Study of Health in Pomerania[J]. Thyroid, 2012, 22(6): 568-574. DOI: 10.1089/thy.2011.0279.
    [23]
    MARSILI A, AGUAYO-MAZZUCATO C, CHEN T, et al. Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity[J]. PLoS One, 2011, 6(6): e20832. DOI: 10.1371/journal.pone.0020832.
    [24]
    FERNANDES GW, BOCCO B, FONSECA TL, et al. The foxo1-inducible transcriptional repressor Zfp125 causes hepatic steatosis and hypercholesterolemia[J]. Cell Rep, 2018, 22(2): 523-534. DOI: 10.1016/j.celrep.2017.12.053.
    [25]
    SAPONARO F, SESTITO S, RUNFOLA M, et al. Selective thyroid hormone receptor-beta (TRβ) agonists: New perspectives for the treatment of metabolic and neurodegenerative disorders[J]. Front Med (Lausanne), 2020, 7: 331. DOI: 10.3389/fmed.2020.00331.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(10)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (698) PDF downloads(63) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return